AZN AstraZeneca PLC Forecast, Technical & Fundamental Analysis

AZN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 09, 2026

AZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 37 cases where AZN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 70%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on AZN as a result. In 46 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

The Moving Average Convergence Divergence (MACD) for AZN just turned positive on September 14, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 26 of 41 cases over the following month. The odds of a continued upward trend are 63%.

AZN moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 193 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.192) is normal, around the industry mean (19.050). P/E Ratio (25.205) is within average values for comparable stocks, (34.258). Projected Growth (PEG Ratio) (1.184) is also within normal values, averaging (5.614). Dividend Yield (0.019) settles around the average of (0.025) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).

The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.